Bioventus (NYSE:BVS) Stock Price Expected to Rise, Craig Hallum Analyst Says

Bioventus (NYSE:BVS) had its target price increased by Craig Hallum from $15.00 to $16.00 in a research note issued on Friday, MarketBeat reports. The firm presently has a “buy” rating on the stock. Craig Hallum’s price target would indicate a potential upside of 90.25% from the stock’s previous close.

Separately, Barrington Research started coverage on shares of Bioventus in a research note on Monday, February 9th. They issued an “outperform” rating and a $13.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $14.25.

Bioventus Trading Down 7.6%

NYSE BVS opened at $8.41 on Friday. The firm’s 50-day moving average is $8.12 and its two-hundred day moving average is $7.50. Bioventus has a 12 month low of $5.81 and a 12 month high of $11.25. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The stock has a market capitalization of $696.04 million, a P/E ratio of -13.79 and a beta of 0.78.

Institutional Investors Weigh In On Bioventus

Large investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd raised its position in Bioventus by 17,156.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after purchasing an additional 5,490 shares in the last quarter. PharVision Advisers LLC acquired a new position in shares of Bioventus during the second quarter worth about $67,000. Covestor Ltd grew its position in shares of Bioventus by 28.0% during the third quarter. Covestor Ltd now owns 9,951 shares of the company’s stock worth $67,000 after buying an additional 2,176 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Bioventus during the second quarter worth approximately $72,000. Finally, HB Wealth Management LLC purchased a new stake in shares of Bioventus during the third quarter worth approximately $72,000. Hedge funds and other institutional investors own 62.94% of the company’s stock.

More Bioventus News

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: Solid Q4 results: revenue of $157.9M (+2.8%) with organic growth of 10%, GAAP EPS $0.21 (vs $0.00 prior year), non‑GAAP EPS $0.24, and cash from operations of $38.0M (up 97%). Management said 2026 guidance reflects continued above‑market revenue growth. Globe Newswire Release
• Positive Sentiment: FY‑2026 guidance modestly ahead of consensus on EPS (0.73–0.77 vs. consensus ~0.72) and revenue guidance of $600–$610M (around consensus). The outlook supports improved earnings and cash generation for the year. Guidance Details
• Positive Sentiment: Management set a $600M–$610M 2026 sales target and said it will accelerate investment in high‑growth areas (PNS, PRP, ultrasonics), signaling reinvestment to fuel medium‑term growth. Seeking Alpha
• Positive Sentiment: Analyst upgrades/price target raises: Craig Hallum raised its PT to $16 (buy) and Barrington Research raised its PT to $14 (outperform), both signaling increased analyst confidence and sizable upside from current levels. Benzinga Street Insider
• Positive Sentiment: Market reaction to the print: shares reacted positively to the beat/guidance when markets first digested the news (shares jumped around the release). This confirms the Q4 beat was meaningful to investors. Investing.com
• Neutral Sentiment: Earnings call materials and full transcript are available for deeper review of commentary around product trends, margin drivers and investment cadence — useful for due diligence but not new company-level catalysts by themselves. Yahoo Transcript Seeking Alpha Presentation
• Negative Sentiment: Despite the largely positive fundamentals and analyst upgrades, the stock is trading lower today — likely due to profit‑taking after the early rally, and because 2026 revenue guidance sits roughly in line with street expectations (limiting an outsized upside surprise). This short‑term selling pressure can mask the longer‑term improvements highlighted above.

About Bioventus

Bioventus, Inc (NYSE: BVS) is a global medical technology company focused on providing innovative therapeutic solutions to enhance patient care in musculoskeletal health. The company develops, manufactures, and markets a range of products designed to promote bone healing, support joint health, and relieve pain non-invasively. Bioventus leverages biologic and biophysical approaches to deliver effective therapies that aim to accelerate recovery times and improve overall patient outcomes.

Bioventus’s product portfolio includes its flagship EXOGEN® Bone Healing System, an ultrasound-based device indicated for non-union fractures and fracture healing enhancement.